Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shuji MIKI
Pharmacokinetics of Ambrisentan, a Novel Drug for Treatment of Pulmonary Arterial Hypertension (PAH), in Japanese Subjects
Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
Related publications
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Improving Outcomes
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension–symptoms and Impact (PAH-SYMPACT) Questionnaire
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adenosine Receptors as Drug Targets for Treatment of Pulmonary Arterial Hypertension
Frontiers in Pharmacology
Pharmacology
Riociguat Is a Novel Medication for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Medical Council
Withdrawal of Long-Term Epoprostenol Therapy in Pulmonary Arterial Hypertension (PAH)
Pulmonary Circulation
Pulmonary
Respiratory Medicine
P2 In-Flight Hypoxaemia in Patients With Pulmonary Arterial Hypertension (PAH)
Thorax
Pulmonary
Respiratory Medicine
Ambrisentan and Tadalafil Up-Front Combination Therapy in Scleroderma-Associated Pulmonary Arterial Hypertension
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
Treatment of Pulmonary Arterial Hypertension in Pregnancy
American Journal of Health-System Pharmacy
Medicine
Health Policy
Pharmacology
Pharmacy
Surgical Treatment of Pulmonary Arterial Hypertension
Advances in Pulmonary Hypertension
